Clinical Trial Detail

NCT ID NCT03595683
Title Pembrolizumab and EDP1503 in Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

melanoma

Therapies

EDP1503 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.